ClinicalTrials.gg

Program

KINE-101

A development code.

Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Kine Sciences.

Furthest: phase 1, since Dec 9, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kine Sciences30 open or runningphase 1since Dec 9, 2025Dec 9, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2025First studies: 3 phase 1 studiesFirst studyNCT07324642, NCT07343323, NCT07343310

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07343323Healthy Volunteers · United States1CompletedJan 31, 202340
NCT07343310Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · South Korea1CompletedApr 14, 20259
NCT07324642Healthy Volunteers · South Korea1CompletedAug 25, 202524

How it is read

Names in the registry

  • “KINE-101”, 3 entries

Codes read as this program: KINE101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.